AzTrials
AzTrials

Hip FracturesFLSSantPauNCT05266755

Hospital Readmission After HIPr Fracture. Impact of a Territorial Fracture Liason Service

A study testing Fracture Territorial Liaison Service afert a Hip fracture in people with Hip Fractures, run by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau at 1 site in Spain.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The International Osteoporosis Foundation (IOF) and the American Society for Bone Research and Mineral Metabolism recommend the creation and implementation of fracture coordination services (FLS) as the most efficient way to address the problem. Read more about this study

Who is it for?
Ages 65 to 99 years
Conditions the study is for
Hip Fractures
What is being tested?
Fracture Territorial Liaison Service afert a Hip fracture
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
120 participants
Where
1 siteSpain
Study dates
15 Mar 2022to 1 Apr 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 to 99 years
  • All sexes
  • No healthy volunteers
  • Older adult

Who may be able to join

  • All hip fractures older than 65 years

Who cannot join

  • Politraumatic fractures
  • Metastasic fractures

Trial locations and contacts

1 site in 1 country.

Jordi M Marcuello, Doctor contact

629315207

jmartinma@santpau.cat

Spain1 site
  • Jordi Martin Marcuello

    Barcelona, Catalonia, 08041

    Jordi M Marcuello, 629315207, jmartinma@santpau.cat

    jmartinma@santpau.cat

Other trials in Spain

About this study

The International Osteoporosis Foundation (IOF) and the American Society for Bone Research and Mineral Metabolism recommend the creation and implementation of fracture coordination services (FLS) as the most efficient way to address the problem. FLS has emerged as a new clinical approach that uses coordinated, multidisciplinary care to improve post-fracture outcomes and reduce recurrent fractures. It is a multidisciplinary and protocolized care model that must guarantee:

  1. Identify fragility fractures and people at risk for a fracture
  2. Fracture risk assessment
  3. Indication for treatment or referral
  4. Improvement in therapeutic compliance
  5. Reduce the risk of falls It is known that patients who have undergone a FLS model (vs no FLS), have lower mortality, lower risk of fracture, with a reduction of 35% and 56%, respectively, during two years of follow-up. One of the most important objectives of the FLS is the proper recognition and treatment of osteoporosis (OP) in patients with fragility fractures. A major problem is the lack of adherence to treatment for OP, and inclusion in an FLS program increases the prescription of bisphosphonates from 17.9% to 76%. In addition, a specific follow-up program means that 73% of patients followed by FLS continue to undergo anti-resorptive treatment after 2 years of having suffered a femur fracture.
Read the detailed description

Hypothesis After a femur fracture due to fragility, upon discharge from surgery at the Hospital de la Santa Creu i Sant Pau, including patients in a regional FLS program will make it possible to complete the study of the patient with fracture, improve adherence to treatment of OP (secondary prevention), and obtain better functional recovery.

Conditions
Hip Fractures
Being tested
Fracture Territorial Liaison Service afert a Hip fracture
Medical subject headings
Hip Fractures

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Fracture Territorial Liaison Service afert a Hip fractureOther

    Give a diferent than the current one way of follow up to the patients with hip fracture

Study groups in NCT05266755
Study groupRoleWhat they receive
Patiens who will receive stanrdar care after hip fracturePlacebo comparatorAll the patients who will be on surgery after a hip fracture will receive after the hospital discharge the standar following we are doing now in our hospital
Receives: Other: Fracture Territorial Liaison Service afert a Hip fracture
Patiens who will receive FLS following after the hip fractureActive comparatorAll the patients who will be on surgery after a hip fracture will receive after the hospital discharge a FLS following, multidisciplinary, with a web and mobile app aplication
Receives: Other: Fracture Territorial Liaison Service afert a Hip fracture

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Deaths

    % of Number of deaths after 1st year o follow up

    Measured: 1 year after discharge

  2. Number of Falls

    Number of Falls 1st year o follow up

    Measured: 1 year after discharge

  3. Percentage of patients with adequated Osteoporotic treatment

    Percentage of patients with adequated osteoporotic treatment

    Measured: 1 year after discharge

Secondary outcomes (1)
  1. Barthel at the end of follow up

    Compare Barthel after hospital discharge with the end of follow up barthel. Minimum is 0 maximum is 100.

    Measured: 1 year after discharge

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Mar 2022
  2. Study start15 Mar 2022 (estimated)
  3. Primary completion1 Jan 2023 (estimated)
  4. Study completion1 Apr 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Multicenter clinical trial. Adult patients who consult the Hospital Emergency Department (ED) of the Hospital de la Santa Creu i Sant Pau (HSCSP) for an FxF PSM as a primary or secondary diagnosis will be selected and will be randomized with a 1:1 distribution to be included in the FLS -CTSPau (intervention group) or to receive usual care (control group). The result of the intervention will be evaluated in terms of health outcomes (re-consultations, hospital readmissions and quality of life).
Masking
None (open label)
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05266755
Sponsor's protocol ID
IIBSP-FLS-2021-114
Acronym
FLSSantPau
Status last verified
Mar 2022
First submitted
23 Feb 2022
Last updated
18 Mar 2022
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Martin Marcuello J, Rodolico A, Britez Carli ML, Puig Campmany M, Blazquez Andion M, de Caso Rodriguez J, Gomis Pastor M, Real Gatius J, de Dios Lopez A, Fradejas Moschino S, Pallares E, Alburquerque J, Lluch Targarona MDM, Mascaro Lamarca J. A territorially coordinated, eHealth-supported fracture liaison service following femur fragility fracture: a pilot randomised controlled trial. Osteoporos Int. 2026 Sep 28. doi: 10.1007/s00198-026-08219-8. Online ahead of print.

    PubMed 42803811

Questions about this trial

What is this clinical trial studying?

A study testing Fracture Territorial Liaison Service afert a Hip fracture in people with Hip Fractures, run by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 18 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Jordi M Marcuello, Doctor (629315207, jmartinma@santpau.cat), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Deaths (time frame: 1 year after discharge). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05266755, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Mar 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in